This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Pamrevlumab
- DrugBank Accession Number
- DB14952
- Background
Pamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Pamrevlumab
- External IDs
- FG-3019
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Pamrevlumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Pamrevlumab. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Pamrevlumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pamrevlumab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Pamrevlumab. Amivantamab The risk or severity of adverse effects can be increased when Pamrevlumab is combined with Amivantamab. Anifrolumab The risk or severity of adverse effects can be increased when Anifrolumab is combined with Pamrevlumab. Ansuvimab The risk or severity of adverse effects can be increased when Pamrevlumab is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Pamrevlumab. Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Pamrevlumab. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- QS5F6VTS0O
- CAS number
- 946415-13-0
References
- General References
- Not Available
- External Links
- Wikipedia
- Pamrevlumab
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Duchenne's Muscular Dystrophy (DMD) 2 3 Active Not Recruiting Treatment Nonresectable Pancreatic Cancer 1 3 Recruiting Treatment Idiopathic Pulmonary Fibrosis (IPF) 2 3 Recruiting Treatment Pancreatic Adenocarcinoma Metastatic / Pancreatic Metastatic Cancer 1 2 Active Not Recruiting Treatment Duchenne's Muscular Dystrophy (DMD) 1 2 Completed Treatment Idiopathic Pulmonary Fibrosis (IPF) 2 2 Terminated Treatment Coronavirus Disease 2019 (COVID‑19) 1 2 Terminated Treatment Diabetic Kidney Disease (DKD) / Diabetic Nephropathy / Type 2 Diabetes Mellitus 1 2 Terminated Treatment Liver Fibrosis Due to Chronic Hepatitis B Infection 1 2, 3 Completed Treatment Coronavirus Disease 2019 (COVID‑19) / COVID-19 Pneumonia / COVID-19 Respiratory Infection 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at May 20, 2019 14:37 / Updated at February 21, 2021 18:55